Basf Aktiengesellschaft

Basf Aktiengsellschaft

Rainer Schlecker

Liliane Unger

Hans-Juergen Teschendorf

Hans P Hofmann

Dieter Lenke

Berthold Behl

Josef Gries

Gerda Von Philipsborn

Ludwig Friedrich

Martin Traut

Hans-Joerg Treiber

Albrecht Franke, Deceased

Andreas Kling

Bernd Janssen

Kurt Ritter

Manfred Raschack

Marco Thyes

Albrecht Franke

Rudolf Kropp

Hans-Jurgen Teschendorf

Claus D Mueller

Horst Kreiskott

Cynthia A Romerdahl

Peter C Thieme

Gerhard Keilhauer

August Amann

Laszlo Szabo

Rolf Kretzschmar

Klaus Ruebsamen

Bernd Ostersehlt

Franz Reicheneder

Peter Schmidt

Stefan Mueller

Dora I Reicheneder

Beatrice Rendenbach

Ulrich Traugott

Hans-J Org Treiber

Triazolopyrimidines of the formula ##STR1## where A, D and X have the meanings stated in the description, and their preparation are described. The novel compounds are suitable for controlling diseases.

Triazolopyrimidones their preparation and use

Triazoloquinazolines, their preparation and use

This invention relates to 1-amino-3-phenoxy-propane-derivatives of formula 1: ##STR1## (in which A, B, R, R.sup.x, X and Z are defined as in the specification described) and methods for their preparation. These compounds may be used as modulators of multidrug resistance in cancer chemotherapy and for circumvention of resistance in the treatment of malaria.

1-amino-3-phenoxy propane derivatives as modulator agents and their

Triazoloquinazolines for the treatment of central nervous disorders

Benzofurancarboxamides having basic substituents, of the formula I ##STR1## in which R.sup.1 and X have the meanings stated in the description, a process for the preparation thereof, and therapeutic agents containing them.

Benzofurancarboxamides having basic substituents, the preparation

A benzofurancarboxamide of the formula: ##STR1## where: X is hydrogen or methoxy,

Benzofurancarboxamides and therapeutic agents

A tetracyclic quinazoline derivative of the formula I: ##STR1## wherein A is C.sub.2-3 -alkylene or C.sub.2-3 -alkylene which is substituted by one or two C.sub.1-4 -alkyl radicals or A is cyclohexylene; X is phenyl, naphthyl or phenyl or naphthyl which is substituted by halogen, nitro, amino, C.sub.1-4 -alkylamino, sulfonylamino, C.sub.1-4 -acylamino, hydroxyl, C.sub.1-4 -alkoxy, --O--(CH.sub.2).sub.2-4 --NR.sup.1 R.sup.2, C.sub.1-4 -alkyl or C.sub.1-4 -alkylsulfonyl, wherein R.sup.1 and R.sup.2 are each hydrogen or C.sub.1-4 -alkyl; or X is thienyl or thienyl which is substituted by chlorine, fluorine, methyl, ethyl, methoxy, ethoxy, nitro or hydroxyl; and R is hydrogen, halogen, nitro, amino, C.sub.1-4 -alkylamino, sulfonylamino, C.sub.1-4 -acylamino, hydroxyl, C.sub.1-4 -alkoxy, --O--(CH.sub.2).sub.2-4 --NR.sup.3 R.sup.4, C.sub.1-4 -alkyl or C.sub.1-4 -alkylsulfonyl, wherein R.sup.3 and R.sup.4 are each hydrogen or C.sub.1-4 -alkyl, and the pharmaceutically acceptable salts thereof. The compounds and compositions of the present invention are effective as antiarrhythmic agents.

Tetracyclic quinazoline derivatives, effective as antiarrythmic agents

9-Amino-2-phenylbicyclo-[3.3.1]nonanes and 9-amino-2-phenylbicyclo[3.3.1]non-2-enes of the formula I ##STR1## where R.sup.1 and R.sup.2 are identical or different and each is hydrogen, halogen, alkyl, alkoxy, dialkylamino, trifluoromethyl, hydroxyl, alkylthio, alkylsulfonyl or nitro, R.sup.3 and R.sup.4 are identical or different and each is hydrogen, alkyl or 1 to 5 or alkenyl or alkynyl of 2 to 5 carbon atoms, or benzyl, it also being possible for R.sup.3 and R.sup.4 together to form a saturated chain which contains from three to seven carbon atoms and can be substituted by phenyl, and where is a single or double bond, are used for producing drugs which act, in particular, on the central nervous system.

9-amino-2-phenylbicyclo[3.3.1]nonanes and

Benzofurancarboxamides having basic substituents and therapeutic agents

Benzofuran derivatives of the formula I ##STR1## where R.sup.1 to R.sup.5 and X have the meanings stated in the description, and therapeutic agents containing these derivatives.

Novel benzofuran derivatives and therapeutic agents containing them

Therapeutic agents containing enantiomers of propafenone, the preparation of the said agents and their use for certain groups of patients.

Therapeutic agents containing enantiomers of propafenone

Benzofuran derivatives of the general formula I ##STR1## where R.sup.1 and R.sup.2 are each hydrogen, alkyl or phenylalkyl, where alkyl in each case is of 1 to 4 carbon atoms, R.sup.3 and R.sup.4 are identical or different and are each hydrogen or C.sub.1 -C.sub.4 -alkyl or together form a 3-membered to 5-membered chain which may be interrupted by an oxygen atom or an NR.sup.1 group, X is --CO--CH.dbd.CH--, --CO--CH.sub.2 --CH.sub.2 --or --CHOH--CH.sub.2 --CH.sub.2 --, n is 2 or 3 and Het is an aromatic 5-membered or 6-membered ring which contains a hetero atom from the group consisting of N, O and S and may additionally contain a (further) N atom, in which the ring may be substituted by C.sub.1 -C.sub.4 -alkyl, fluorine, chlorine, bromine, NH.sub.2 or NR.sup.1 R.sup.2, where R.sup.1 and R.sup.2 have the abovementioned meanings, the use of these benzofuran derivatives for the preparation of pharmaceutical, in particular antiulcerogenic, agents, and these agents themselves are described.

Benzofuran derivatives and antiulcerogenic agents containing same

Novel 1-phenyl-4(1H)-pyridazinone-imines of the formula (I) ##STR1## which are substituted at the imine nitrogen, and their addition salts with a physiologically tolerated acid, processes for their preparation, pharmaceutical formulations containing these compounds, and their use as drugs, in particular as antidepressants, antiparkinson drugs and antihypotonic agents.

Novel pyridazinone-imines and their physiologically tolerated addition

Sulfonates of hydroxycoumarins of the formula I ##STR1## where R.sup.1 and R.sup.2 are identical or different and are each hydrogen, halogen or alkyl of 1 to 5 carbon atoms which can be substituted by --NR.sup.4 R.sup.5, --OR.sup.4 or --OC(O)R.sup.4, where R.sup.4 and R.sup.5 are identical or different and are each hydrogen or alkyl of 1 to 4 carbon atoms, or R.sup.1 and R.sup.2 are each a carboxylic acid group --OC(O)R.sup.4 or a carboxamido radical, with the proviso that R.sup.1 is not methyl when R.sup.2 is hydrogen, or R.sup.1 and R.sup.2 together form a --(CH.sub.2).sub.n -- chain where n is 3-5, and R.sup.3 is a straight-chain or branched alkyl radical of 1 to 8 carbon atoms or cycloalkyl of 3 to 8 carbon atoms, each of which can be substituted by halogen, --OR.sup.4, --NR.sup.4 R.sup.5, --CN or phenyl, or R.sup.3 is a straight-chain or branched alkenyl radical of 3 to 8 carbon atoms, an amino group -- NR.sup.4 R.sup.5, or phenyl or naphthyl, each of which is unsubstituted or monosubstituted or polysubstituted by --OR.sup.4, --NR.sup.4 R.sup.5, --NO.sub.2, halogen, --SR.sup.4, --S(O)R.sup.4, --OS(O)R.sup.4, --SCF.sub.3, --OS(O)CF.sub.3, --CN, --C(O)R.sup.4, --OC(O)R.sup.4, --NHC(O)R.sup.4, --CF.sub.3, C.sub.1 -C.sub.4 -alkyl or a combination of these substituents, a process for their preparation, drugs containing these compounds, and compounds of the formula I, in which R.sup.1 is methyl and R.sup.2 is hydrogen, for use as drugs.

Sulfonates of hydroxycoumarins

Growing community of inventors

Bissersheim, Germany

Rainer Schlecker